About Morphotek
Morphotek is a company based in Exton (United States) founded in 2000 was acquired by Eisai in March 2007. Morphotek has raised $79.5 million across 18 funding rounds from investors including Eisai, dsm-firmenich and HHS. Morphotek operates in a competitive market with competitors including Moderna, BeiGene, Aclaris Therapeutics, Incyte and Ultragenyx, among others.
- Headquarter Exton, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Morphotek
Morphotek has successfully raised a total of $79.5M across 18 strategic funding rounds. The most recent funding activity was a Grant round of $947 thousand completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Morphotek
Morphotek has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Eisai, dsm-firmenich and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors
|
Locked | Locked | Locked | |
|
Investments are directed toward young firms in pharmaceuticals and biotech.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm that does early stage investments in the US
|
Locked | Locked | Locked |
Investor details for Morphotek
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Morphotek
Investment portfolio details for Morphotek
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Morphotek
Detailed financials for Morphotek
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Morphotek Comparisons
Peer comparison for Morphotek
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Morphotek
Morphotek operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Aclaris Therapeutics, Incyte and Ultragenyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Morphotek
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Morphotek
Complete news archive for Morphotek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Morphotek
Morphotek was founded in 2000.
Morphotek is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Morphotek is a funded company, having raised a total of $79.5M across 18 funding rounds to date.
Morphotek develops biological-based products to treat cancer, inflammation, and infectious diseases. Has several monoclonal antibodies (mAbs) in clinical development for cancer and inflammatory disease. Its lead program, farletuzumab is for patients with platinum-sensitive, relapsed ovarian cancer (received orphan drug designation) and 1st line non-small cell lung cancer. Its other lead antibody monoclonal programs, amatuximab, and ontuxizumab. Amatuximab, ontuxizumab has received orphan drug designation for malignant pleural mesothelioma and for sarcoma respectively. Its other investigational mAbs programs are against inflammatory and infectious diseases.
Morphotek's top competitors include Moderna, BeiGene and Escient Pharmaceuticals.
Morphotek has 16 investors. Key investors include Eisai, dsm-firmenich, HHS, Flagship Pioneering, and DARPA.